“Cancer Marker – Male” has been added to your cart.
View cart -
د.إ3,250.00
The BCR/ABL – Quantitative test is a highly sensitive molecular diagnostic assay used to detect and quantify the BCR-ABL fusion gene, a key biomarker in chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias (ALL). Utilizing real-time PCR technology, it provides precise measurement of BCR-ABL transcript levels, enabling accurate disease monitoring and treatment response assessment.
Sample Type : Whole Blood
Methodology : Real time PCR
TAT : 8-10 Days
-
د.إ370.00
The Cancer Antigen 72-4 (CA 72-4) Test is a diagnostic blood test used to detect and monitor gastrointestinal cancers, particularly gastric and colorectal cancer. It measures CA 72-4, a tumor-associated glycoprotein, aiding in early detection, treatment monitoring, and recurrence assessment.
Sample Type : Serum
Methodology : TBA
TAT : 7 Days
-
د.إ650.00
Includes the following parameters:
- Alpha-Fetoprotein (AFP)
- CA 19.9, Serum (Pancreatic Cancer Marker)
- Carcinoembryonic Antigen (CEA), Serum
- Prostate-Specific Antigen (PSA), Total Serum
- Prostate-Specific Antigen (PSA), Free Serum
- Human Chorionic Gonadotropin (HCG)
-
د.إ550.00
Sample Type : Serum
Methodology : TBA
TAT : 10 Days
-
د.إ13,000.00
Liquid HALLMARK is a comprehensive liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw to detect and monitor cancer.
Sample Type : Serum
Methodology : Ultra-deep sequencing using Lucence’s proprietary AmpliMARK™ technology
TAT : 8-10 Days
-
د.إ35,000.00
The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation.
-
د.إ3,500.00
The PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment.
-
د.إ850.00
Sample Type : Serum
Methodology : Electrochemiluminescence
TAT : 15 Days
